✨ Free AI Report
Revance Therapeutics, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Revance Therapeutics, Inc.
Company Research

Revance Therapeutics, Inc.: Business Overview, Financials & Competitive Analysis

Revance Therapeutics is a biotechnology company that develops and commercializes neuromodulators for aesthetic and therapeutic indications. The company was acquired by Crown Laboratories in February 2025, transitionin...

Analyst-debate audio for Revance Therapeutics, Inc.

AskCyborg analysts argue the bull and bear cases for Revance Therapeutics, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
7/ 10Strong

Cyborg Score thesis

Rapidly commercializing neuromodulator positioned to disrupt the aesthetics market with differentiated long-duration botulinum...

Read the full analyst-debate transcript →
Industry Pharmaceuticals
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 28, 2026
AI-Verified Research
30+ Page Report

Get the Latest Revance Therapeutics, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Revance Therapeutics, Inc. Overview

Pro stress-test →

Revance Therapeutics is a biotechnology company that develops and commercializes neuromodulators for aesthetic and therapeutic indications. The company was acquired by Crown Laboratories in February 2025, transitioning from public to private ownership. DAXXIFY (daxibotulinumtoxinA-lanm), its core product, is the fastest-growing neurotoxin in the U.S., reaching one million vials distributed by September 2025.

Strategic Profile

Pro stress-test →

Revance's strategy focuses on capturing market share from incumbents like Allergan's Botox by offering a differentiated product profile in a market projected to reach $8 billion. As a Crown subsidiary, the business concentrates on core aesthetic and therapeutic product lines including DAXXIFY and the RHA Collection of dermal fillers. The company operates internationally through partnerships with Teoxane SA in Switzerland and Shanghai Fosun Pharmaceutical in China for product commercialization.

Competitive Landscape

Pro stress-test →

Revance competes directly with Allergan's BOTOX in the botulinum toxin market, differentiating through longer duration and improved movement profiles. Key competitors include established players in neuromodulators and dermal fillers. Revance's proprietary peptide technology and rapid commercialization of DAXXIFY position it as a disruptor in the $8 billion aesthetic injectables market.

Industry Context

Revance Therapeutics, Inc. operates in Pharmaceuticals.

Key facts

Founded: 1999 · Headquarters: Nashville, US · Employees: 597 · Revenue: $256.95M

What the analysts stress-tested

The top findings that survived the multi-agent debate for Revance Therapeutics, Inc..

  • DAXXIFY is the fastest-growing neurotoxin in the U.S., with one million vials distributed by September 2025
  • Acquired by Crown Laboratories in February 2025 at $3.65 per share, transitioning from NASDAQ-traded to private subsidiary
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • February 2025Acquisition by Crown Laboratories completed at $3.65 per share
  • September 2025DAXXIFY achieved one million vials distributed milestone
  • +1 moreTrack every material event for Revance Therapeutics, Inc. as it happens. Explore monitoring →
Get alerted when Revance Therapeutics, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

BOTOXLeading botulinum toxin for cosmetic and therapeutic indications→XeominBotulinum toxin alternative for aesthetic and therapeutic use→DysportBotulinum toxin for aesthetic and therapeutic applications→

Compare Revance Therapeutics, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Revance Therapeutics, Inc. operates in Pharmaceuticals. See how the rest of the sector scores on the Cyborg framework.

Browse Pharmaceuticals research →
NEW · MCP server

Ask your AI assistant about Revance Therapeutics, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Revance Therapeutics, Inc. and its top competitor on Cyborg Score”
“What did Revance Therapeutics, Inc. do this quarter?”
“Is Revance Therapeutics, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Revance Therapeutics, Inc. do?+
Revance Therapeutics is a biotechnology company that develops and commercializes neuromodulators for aesthetic and therapeutic indications. The company was acquired by Crown Laboratories in February 2025, transitionin...
What is Revance Therapeutics, Inc.'s Cyborg Score?+
Revance Therapeutics, Inc. has a Cyborg Score of 7/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Revance Therapeutics, Inc.'s main competitors?+
Named competitors include BOTOX, Xeomin, Dysport. The full competitive landscape is in the AskCyborg report.
How can I get the full Revance Therapeutics, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Revance Therapeutics, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Revance Therapeutics, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Pharmaceuticals research

Companies in the same sector and named competitors, ranked by Cyborg Score.

7Novartis AG7Recordati Industria Chimica e Farmaceutica SpA6CSPC Innovation Pharmaceutical Co., Ltd.